INDIAN BENCHMARKS at all-time high levels
INDIAN
BENCHMARKS
end at all-time closing high , sharp decline in India's current account deficit
during the December quarter provided the perfect fuel vindicating foreign fund
buying in the past few sessions to boost the markets.
Further, Lupin has announced that it
has received final approval for its Doxycycline Capsules USP, 50 mg,
75 mg, and 100 mg from the United States Food and Drugs
Administration (FDA) to market a generic version of Aqua Pharmaceuticals
Monodox Capsules 50 mg, 75 mg, and 100 mg. ONGC and Oil India Ltd are planning to
buy 10% stake in Indian Oil Corp from the government at Rs 220 per share,
aggregating about Rs 5,300 crore.
The
crucial resistance for Nifty is now seen at 6415 and above this 6450.
Support for the immediate term is now placed at 6340 and next support
will be 6260.
0 comments:
Post a Comment